More evidence that bisphosphonates do not increase the risk of atrial fibrillation (AF) or flutter
Bisphosphonates don’t increase the risk of atrial fibrillation, according to the study Oral Bisphosphonates and Risk of Atrial Fibrillation and Flutter in Women: A Self-Controlled Case-Series Safety, published in PLoS One on March 2009. The authors used a self-control case series analysis to study nearly 400,000 women from the UK General Practice Research Database. They […]
SMC: Zoledronic acid (Aclasta) not recommended for treatment of osteoporosis in men
This is the advice published by the Scottish Medicines Consortium about the use of zoledronic acid for the treatment of osteoporosis in men. ADVICE: in the absence of a submission from the holder of the marketing authorisation. zoledronic acid 5mg (Aclasta®) is not recommended for use within NHSScotland for the treatment of osteoporosis in men […]
Zoledronic acid: summary review and side effects profile published on the NPS RADAR
An excerpt of the summary review and side effects profile of Zoledronic acid, published on the australian NPS RADAR: Zoledronic acid is an intravenous bisphosphonate. It is given as a once-yearly infusion for osteoporosis in women with any fracture, and in men with a minimal-trauma hip fracture. Some patients may prefer zoledronic acid to oral […]